Press release
Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche
DelveInsight's "Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Facioscapulohumeral Muscular Dystrophy, historical and forecasted epidemiology as well as the Facioscapulohumeral Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Facioscapulohumeral Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Facioscapulohumeral Muscular Dystrophy Market Forecast [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Facioscapulohumeral Muscular Dystrophy Market Report:
*
The Facioscapulohumeral Muscular Dystrophy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In July 2024, The University of Kansas (KU) Medical Center in the US has shared initial findings from the Phase I/II trial of Avidity Biosciences' drug, del-brax (delpacibart braxlosiran), aimed at treating facioscapulohumeral muscular dystrophy (FSHD). As the trial's study site, KU Medical Center reported early results suggesting that del-brax may substantially reduce the expression of the DUX4 gene.
*
In 2023, the total prevalent cases of FSHD in the 7MM were approximately 79,000, with an expected increase by 2034.
*
In 2023, the United States accounted for roughly 40% of the total cases in the 7MM, with these numbers expected to rise by 2034.
*
According to DelveInsight's analysts, there were approximately 6,000 cases of FSHD1 and about 300 cases of FSHD2 in Japan in 2023. These numbers are expected to decrease during the forecast period (2024-2034).
*
According to DelveInsight's consultant estimates, the majority of cases among the seven major markets are attributed to FSHD1. In 2023, approximately 95% of the prevalent cases were FSHD1, as compared to FSHD2.
*
During the forecast period (2024-2034), pipeline candidates like losmapimod (Fulcrum Therapeutics) and RO7204239/GYM-329/RG-6237 (Hoffmann-La Roche) are anticipated to contribute to the growth of the FSHD market size.
*
In 2023, the total number of treated cases of FSHD in the 7MM was approximately 34,000, with an anticipated increase by 2034.
*
In 2023, the highest number of age-specific cases of FSHD in the 7MM was observed in patients aged 50 years and above, totaling approximately 23,000. These numbers are projected to rise in the forecast period.
*
Key Facioscapulohumeral Muscular Dystrophy Companies: Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others
*
Key Facioscapulohumeral Muscular Dystrophy Therapies: GYM329 (RO7204239/RG 6237), Losmapimod, ATYR1940, Losmapimod, RO7204239, MYO-029, AOC 1020, and others
*
The Facioscapulohumeral Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Facioscapulohumeral Muscular Dystrophy pipeline products will significantly revolutionize the Facioscapulohumeral Muscular Dystrophy market dynamics.
Facioscapulohumeral Muscular Dystrophy Overview
Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic muscle disorder characterized by progressive muscle weakness and wasting, primarily affecting the muscles of the face (facio-), shoulder blades (scapulo-), and upper arms (humeral). It is one of the most common forms of muscular dystrophy.
Get a Free sample for the Facioscapulohumeral Muscular Dystrophy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market [https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Facioscapulohumeral Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Facioscapulohumeral Muscular Dystrophy Epidemiology Segmentation:
The Facioscapulohumeral Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Facioscapulohumeral Muscular Dystrophy
*
Prevalent Cases of Facioscapulohumeral Muscular Dystrophy by severity
*
Gender-specific Prevalence of Facioscapulohumeral Muscular Dystrophy
*
Diagnosed Cases of Episodic and Chronic Facioscapulohumeral Muscular Dystrophy
Download the report to understand which factors are driving Facioscapulohumeral Muscular Dystrophy epidemiology trends @ Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Facioscapulohumeral Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facioscapulohumeral Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Facioscapulohumeral Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Facioscapulohumeral Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Facioscapulohumeral Muscular Dystrophy Therapies and Key Companies
*
GYM329 (RO7204239/RG 6237): Roche
*
Losmapimod: Fulcrum Therapeutics
*
ATYR1940: aTyr Pharma, Inc.
*
Losmapimod: Fulcrum Therapeutics
*
RO7204239: Hoffmann-La Roche
*
MYO-029: Pfizer
*
AOC 1020: Avidity Biosciences, Inc
Discover more about therapies set to grab major Facioscapulohumeral Muscular Dystrophy market share @ Facioscapulohumeral Muscular Dystrophy Treatment Landscape [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Facioscapulohumeral Muscular Dystrophy Market Strengths
*
Government registries aim to facilitate and accelerate academic and clinical research in FSHD, leading to the increase in knowledge and awareness.
*
Currently, there are no approved therapies to treat FSHD, so there will be a high chance of reimbursement for the upcoming therapies, as the cost of the treatment will be very high, and this will be first mover advantage for the government to reimburse the drugs
Facioscapulohumeral Muscular Dystrophy Market Opportunities
*
Limitations in current drug therapies may lead to the need for more and more reliable treatment, which could also fuel demand growth
*
Developing novel therapeutics and individualized medical care based on biomarkers will present profitable commercial prospects
Scope of the Facioscapulohumeral Muscular Dystrophy Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Facioscapulohumeral Muscular Dystrophy Companies: Fulcrum Therapeutics, aTyr Pharma, Inc., Fulcrum Therapeutics, Hoffmann-La Roche, Pfizer, Avidity Biosciences, Inc, and others
*
Key Facioscapulohumeral Muscular Dystrophy Therapies: GYM329 (RO7204239/RG 6237), Losmapimod, ATYR1940, Losmapimod, RO7204239, MYO-029, AOC 1020, and others
*
Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment: Facioscapulohumeral Muscular Dystrophy current marketed and Facioscapulohumeral Muscular Dystrophy emerging therapies
*
Facioscapulohumeral Muscular Dystrophy Market Dynamics: Facioscapulohumeral Muscular Dystrophy market drivers and Facioscapulohumeral Muscular Dystrophy market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Facioscapulohumeral Muscular Dystrophy Unmet Needs, KOL's views, Analyst's views, Facioscapulohumeral Muscular Dystrophy Market Access and Reimbursement
To know more about Facioscapulohumeral Muscular Dystrophy companies working in the treatment market, visit @ Facioscapulohumeral Muscular Dystrophy Clinical Trials and Treatment [https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Facioscapulohumeral Muscular Dystrophy Market Report Introduction
2. Executive Summary for Facioscapulohumeral Muscular Dystrophy
3. SWOT analysis of Facioscapulohumeral Muscular Dystrophy
4. Facioscapulohumeral Muscular Dystrophy Patient Share (%) Overview at a Glance
5. Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance
6. Facioscapulohumeral Muscular Dystrophy Disease Background and Overview
7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Facioscapulohumeral Muscular Dystrophy
9. Facioscapulohumeral Muscular Dystrophy Current Treatment and Medical Practices
10. Facioscapulohumeral Muscular Dystrophy Unmet Needs
11. Facioscapulohumeral Muscular Dystrophy Emerging Therapies
12. Facioscapulohumeral Muscular Dystrophy Market Outlook
13. Country-Wise Facioscapulohumeral Muscular Dystrophy Market Analysis (2020-2034)
14. Facioscapulohumeral Muscular Dystrophy Market Access and Reimbursement of Therapies
15. Facioscapulohumeral Muscular Dystrophy Market Drivers
16. Facioscapulohumeral Muscular Dystrophy Market Barriers
17. Facioscapulohumeral Muscular Dystrophy Appendix
18. Facioscapulohumeral Muscular Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=facioscapulohumeral-muscular-dystrophy-market-to-show-remarkable-growth-trends-from-2024-to-2034-delveinsight-reports-fulcrum-therapeutics-atyr-pharma-fulcrum-therapeutics-hoffmannla-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Facioscapulohumeral Muscular Dystrophy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fulcrum Therapeutics, aTyr Pharma, Fulcrum Therapeutics, Hoffmann-La Roche here
News-ID: 3744499 • Views: …
More Releases from ABNewswire
Ottawa Window Medics Reinforces Its "Restore, Don't Replace" Mission, Helping Ho …
Ottawa Window Medics, the region's trusted expert in window and door repair and restoration, today reaffirmed its commitment to transforming how homeowners address foggy, hazy, or moisture-damaged windows. The company's proven "Restore, Don't Replace" philosophy delivers substantial savings-often between 50% and 70% compared to full replacement-while extending the lifespan of existing windows and doors by as much as 20 additional years.
OTTAWA, ON - October 30, 2025 - Ottawa Window Medics,…
Super Daddy Universe Launches a Heartfelt Mission to Redefine Fatherhood
In a world that often celebrates superheroes with capes and powers, one brand has set out to celebrate a different kind of hero - Dad. Super Daddy Universe, a new and emotionally-driven eCommerce brand, is redefining the way fathers and children connect through play, creativity, and shared memories.
October 30, 2025 - In a world that often celebrates superheroes with capes and powers, one brand has set out to celebrate a…
Suncheon Joins Global Conservation Leaders as South Korea's "Ecological Capital" …
Suncheon has emerged as South Korea's "Ecological Capital," joining the world's conservation leaders with a vision that unites environmental restoration and healing tourism.
Image: https://www.abnewswire.com/upload/2025/10/308ee6f9bf4c9e478e007c6089e0f02a.jpg
(Image: Flocks of hooded cranes descend over the golden reeds of Suncheonman Bay. Each autumn, the wetlands turn into a sanctuary for migratory birds-and for visitors seeking to witness one of Asia's most poetic encounters between nature and life. Photo courtesy of Suncheon City)
SUNCHEON, South Korea -…
Travel Packages to Peru - Early Bird Deals by Travel Agency Book and Vamonos: Di …
Image: https://www.abnewswire.com/upload/2025/10/c7ea28cc5f1df5a8d8ec4b0c90df4d36.jpg
Book and Vamonos, a specialist in Peruvian travel, is thrilled to announce a 15% Early Bird Discount on all 2026 Peru travel packages and Peru tours, valid for bookings made by December 31, 2025. These designed itineraries are crafted to make exploring Peru's ancient wonders, vibrant culture, and unparalleled cuisine effortless, authentic, and truly unforgettable. By planning their trip with Book and Vamonos [https://www.bookandvamonos.com/?utm_source=abnewswire&utm_medium=pr&utm_campaign=press_october_home], travelers can travel more and…
More Releases for Facioscapulohumeral
Facioscapulohumeral Muscular Dystrophy (FSHD) Market Massive Growth opportunity …
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle disorder characterized by progressive weakness of facial, shoulder, and upper arm muscles, and eventually lower body muscles. It is the third most common type of muscular dystrophy, affecting approximately 1 in 8,000 to 1 in 20,000 individuals worldwide.
FSHD is typically caused by abnormal expression of the DUX4 gene due to genetic mutations on chromosome 4. While there is currently no approved…
Facioscapulohumeral Muscular Dystrophy Market Expected to Evolve Through 2034 Am …
Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most prevalent forms of muscular dystrophy, characterized by progressive skeletal muscle weakness that initially affects the face, shoulders, and upper arms. The condition is genetically linked to abnormal expression of the DUX4 gene, most commonly caused by contraction of the D4Z4 repeat on chromosome 4. FSHD can significantly impact mobility, quality of life, and daily function, though disease progression varies widely among…
Facioscapulohumeral Muscular Dystrophy Market Set for Growth Through 2034, Drive …
Facioscapulohumeral Muscular Dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy, is a rare and progressive genetic disorder characterized by muscle weakness and atrophy, typically affecting the face, shoulder blades, and upper arms. With no approved disease-modifying therapies currently available, FSHD poses a significant unmet need for patients and healthcare systems globally.
DelveInsight's latest report, "Facioscapulohumeral Muscular Dystrophy - Market Insight, Epidemiology, and Market Forecast - 2034," offers an…
Facioscapulohumeral Muscular Dystrophy Clinical Trials, Treatment Drugs, Pipelin …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
Facioscapulohumeral Muscular Dystrophy Pipeline 2024 | Fulcrum Therapeutics, Dyn …
DelveInsight's, "Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the Facioscapulohumeral Muscular Dystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Facioscapulohumeral Muscular Dystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Facioscapulohumeral Muscular Dystrophy pipeline products in this…
Facioscapulohumeral Muscular Dystrophy Market Size, Share, Trends, Demand, Growt …
Global Facioscapulohumeral Muscular Dystrophy Market study by Data Bridge Market Research provides details about the market dynamics affecting the Facioscapulohumeral Muscular Dystrophy market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.
A number of estimations and calculations have been included in the first class Facioscapulohumeral Muscular Dystrophy market report by assuming definite base year and the…
